Monopar raises $92M, extends runway to 2027; ALXN1840 NDA delayed to mid-2026

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~2 min read

Key Changes

• high

  Cash position jumped from $54.6M to $137.5M following September 2025 capital raise that netted $91.9M after concurrent $35M buyback from major shareholder Tactic Pharma. Management extended cash runway guidance by one year to end of 2027.

  MD&A: Liquidity verify on EDGAR →
• high

  NDA submission for lead asset ALXN1840 delayed from early 2026 to mid-2026 due to ongoing FDA dialogue on submission package refinement. Company added cautionary language about acceptance and approval uncertainty.

  MD&A: Regulatory Milestones verify on EDGAR →
• high

  New Phase 3 subgroup data presented at AAN in April 2026 showed ALXN1840 reduced neurologic worsening to 9% vs 25% on standard of care (p=0.038) in Wilson disease patients with neurologic symptoms, addressing critical unmet need.

  MD&A: Clinical Data verify on EDGAR →